Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Lymphangiosis carcinomatosa
ADR ID BADD_A08137
ADR Hierarchy
01      Blood and lymphatic system disorders
01.09      Spleen, lymphatic and reticuloendothelial system disorders
01.09.01      Lymphatic system disorders NEC
01.09.01.027      Lymphangiosis carcinomatosa
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.22      Metastases
16.22.02      Metastases to specified sites
16.22.02.009      Lymphangiosis carcinomatosa
24      Vascular disorders
24.09      Lymphatic vessel disorders
24.09.02      Lymphangiopathies
24.09.02.007      Lymphangiosis carcinomatosa
Description Not Available
MedDRA Code 10053132
MeSH ID Not Available
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Lymphangitis carcinomatosis | Lymphangiosis carcinomatosa
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00014Abiraterone0.000576%
BADD_D00047Afatinib0.000278%
BADD_D00193Axitinib0.000139%
BADD_D00474Cisplatin0.000347%
BADD_D00798Eribulin0.000347%
BADD_D00858Everolimus0.000666%
BADD_D01008Gefitinib0.000208%
BADD_D01254Lenvatinib0.000139%
BADD_D01257Letrozole0.000321%
BADD_D01601Olaparib0.000208%
BADD_D01629Osimertinib0.000695%
BADD_D01633Oxaliplatin0.000347%
BADD_D01687Pazopanib0.000208%
BADD_D01835Pregabalin0.000092%
BADD_D01922Regorafenib0.000278%
The 1th Page    1    Total 1 Pages